Starpharma Holdings (SPL)
Starpharma Holdings Ltd. engages in the research and development of dendrimer products for pharmaceutical, life science and other applications. It has three core development programs: VivaGel portfolio, Drug delivery and Agrochemicals, which develops a number of products internally and others via commercial partnerships. Its product is VivaGel, a gel-based formulation of a proprietary dendrimer and is under clinical development for the treatment and prevention of bacterial vaginosis and also as a vaginal microbicide to prevent the transmission of sexually transmitted infections including HIV and genital herpes. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
|Market Price at 17-01-2018||$1.38|
|Price to Earnings Ratio||37.52|
|Market Capitalisation||$509.34 (million)|
|Return on Equity (ROE)||12.07%|